|
1
|
Moreno-Acosta P, Carrillo S, Gamboa O,
Acosta Y, Balart-Serrad J, Magne N, Melo-Uribef MA and Romero-Rojas
AE: Expresión de marcadores hipóxicos y glucolíticos CAIX, GLUT-1,
HKII y su relación con la respuesta temprana al tratamiento en
carcinoma escamocelular de cuello uterino. Progresos de Obstetricia
y Ginecología. 56:404–413. 2013. View Article : Google Scholar
|
|
2
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vaupel P and Harrison L: Tumor hypoxia:
Causative factors, compensatory mechanisms and cellular response.
Oncologist. 9:(Suppl 5). S4–S9. 2004. View Article : Google Scholar
|
|
5
|
Pili R and Donehower RC: Is HIF-1 alpha a
valid therapeutic target? J Natl Cancer Inst. 95:498–499. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gatenby RA and Gillies RJ: Glycolysis in
cancer: A potential target for therapy. Int J Biochem Cell Biol.
39:1358–1366. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lamkin DM, Spitz DR, Shahzad MM, Zimmerman
B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK and
Lutgendorf SK: Glucose as a prognostic factor in ovarian carcinoma.
Cancer. 115:1021–1027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan Y and Zong WX: Hacking hexokinase
halts tumor growth. Cancer Biol Ther. 7:1136–1138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee WY, Huang SC, Hsu KF, Tzeng CC and
Shen WL: Roles for hypoxia-regulated genes during cervical
carcinogenesis: Somatic evolution during the
hypoxia-glycolysis-acidosis sequence. Gynecol Oncol. 108:377–384.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xue F, Lin LL, Dehdashti F, Miller TR,
Siegel BA and Grigsby PW: F-18 fluorodeoxyglucose uptake in primary
cervical cancer as an indicator of prognosis after radiation
therapy. Gynecol Oncol. 101:147–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Behrooz A and Ismail-Beigi F: Dual control
of glut1 glucose transporter gene expression by hypoxia and by
inhibition of oxidative phosphorylation. J Biol Chem.
272:5555–5562. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hatzivassiliou G, Andreadis C and Thompson
CB: Akt-directed metabolic alterations in cancer. Drug Discovery
Today: Disease Mechanisms. 2:255–262. 2005. View Article : Google Scholar
|
|
13
|
Gottlob K, Majewski N, Kennedy S, Kandel
E, Robey RB and Hay N: Inhibition of early apoptotic events by
Akt/PKB is dependent on the first committed step of glycolysis and
mitochondrial hexokinase. Genes Dev. 15:1406–1418. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mayer A, Höckel M and Vaupel P: Endogenous
hypoxia markers: Case not proven! Adv Exp Med Biol. 614:127–136.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lal A, Peters H, St Croix B, Haroon ZA,
Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ and
Riggins GJ: Transcriptional response to hypoxia in human tumors. J
Natl Cancer Inst. 93:1337–1343. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rafajová M, Zatovicová M, Kettmann R,
Pastorek J and Pastoreková S: Induction by hypoxia combined with
low glucose or low bicarbonate and high posttranslational stability
upon reoxygenation contribute to carbonic anhydrase IX expression
in cancer cells. Int J Oncol. 24:995–1004. 2004.PubMed/NCBI
|
|
17
|
Vordermark D, Kaffer A, Riedl S, Katzer A
and Flentje M: Characterization of carbonic anhydrase IX (CA IX) as
an endogenous marker of chronic hypoxia in live human tumor cells.
Int J Radiat Oncol Biol Phys. 61:1197–1207. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pastorek J, Pastoreková S, Callebaut I,
Mornon JP, Zelník V, Opavský R, Zat'ovicová M, Liao S, Portetelle
D, Stanbridge EJ, et al: Cloning and characterization of MN, a
human tumor-associated protein with a domain homologous to carbonic
anhydrase and a putative helix-loop-helix DNA binding segment.
Oncogene. 9:2877–2888. 1994.PubMed/NCBI
|
|
19
|
Lyshchik A, Higashi T, Hara T, Nakamoto Y,
Fujimoto K, Doi R, Imamura M, Saga T and Togashi K: Expression of
glucose transporter-1, hexokinase-II, proliferating cell nuclear
antigen and survival of patients with pancreatic cancer. Cancer
Invest. 25:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pouysségur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase II: Cancer's double-edged sword acting as both
facilitator and gatekeeper of malignancy when bound to
mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oh JM, Ryoo IJ, Yang Y, Kim HS, Yang KH
and Moon EY: Hypoxia-inducible transcription factor (HIF)-1 alpha
stabilization by actin-sequestering protein, thymosin beta-4 (TB4)
in Hela cervical tumor cells. Cancer Lett. 264:29–35. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dunst J, Kuhnt T, Strauss HG, Krause U,
Pelz T, Koelbl H and Haensgen G: Anemia in cervical cancers: Impact
on survival, patterns of relapse, and association with hypoxia and
angiogenesis. Int J Radiat Oncol Biol Phys. 56:778–787. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang CC, Murphy SP and Ferrone S:
Differential in vivo and in vitro HLA-G expression in melanoma
cells: Potential mechanisms. Hum Immunol. 64:1057–1063. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Winter WE III, Maxwell GL, Tian C, Sobel
E, Rose GS, Thomas G and Carlson JW: Association of hemoglobin
level with survival in cervical carcinoma patients treated with
concurrent cisplatin and radiotherapy: A gynecologic oncology group
study. Gynecol Oncol. 94:495–501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mayer A, Höckel M and Vaupel P: Carbonic
anhydrase IX expression and tumor oxygenation status do not
correlate at the microregional level in locally advanced cancers of
the uterine cervix. Clin Cancer Res. 11:7220–7225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haensgen G, Krause U, Becker A, Stadler P,
Lautenschlaeger C, Wohlrab W, Rath FW, Molls M and Dunst J: Tumor
hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol
Biol Phys. 50:865–872. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Green J, Kirwan J, Tierney J, Vale C,
Symonds P, Fresco L, Williams C and Collingwood M: Concomitant
chemotherapy and radiation therapy for cancer of the uterine
cervix. Cochrane Database Syst Rev: CD002225. 2005. View Article : Google Scholar
|
|
29
|
Symonds R and Foweraker K: Principles of
chemotherapy and radiotherapy. Current Obstetrics &
Gynaecology. 16:100–106. 2006. View Article : Google Scholar
|
|
30
|
Airley RE, Loncaster J, Raleigh JA, Harris
AL, Davidson SE, Hunter RD, West CM and Stratford IJ: GLUT-1 and
CAIX as intrinsic markers of hypoxia in carcinoma of the cervix:
Relationship to pimonidazole binding. Int J Cancer. 104:85–91.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bachtiary B, Schindl M, Pötter R, Dreier
B, Knocke TH, Hainfellner JA, Horvat R and Birner P: Overexpression
of hypoxia-inducible factor 1alpha indicates diminished response to
radiotherapy and unfavorable prognosis in patients receiving
radical radiotherapy for cervical cancer. Clin Cancer Res.
9:2234–2240. 2003.PubMed/NCBI
|
|
32
|
Moreno-Acosta P, Gamboa O, de Gomez M
Sanchez, Cendales R, Diaz GD, Romero A, Serra J Balart, Conrado Z,
Levy A, Chargari C and Magné N: IGF1R gene expression as a
predictive marker of response to ionizing radiation for patients
with locally advanced HPV16-positive cervical cancer. Anticancer
Res. 32:4319–4325. 2012.PubMed/NCBI
|
|
33
|
Birner P, Schindl M, Obermair A, Plank C,
Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible
factor 1alpha is a marker for an unfavorable prognosis in
early-stage invasive cervical cancer. Cancer Res. 60:4693–4696.
2000.PubMed/NCBI
|
|
34
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yen TC, See LC, Lai CH, Yah-Huei CW, Ng
KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR and Hsueh S: 18F-FDG
uptake in squamous cell carcinoma of the cervix is correlated with
glucose transporter 1 expression. J Nucl Med. 45:22–29.
2004.PubMed/NCBI
|
|
36
|
Kim BW, Cho H, Chung JY, Conway C, Ylaya
K, Kim JH and Hewitt SM: Prognostic assessment of hypoxia and
metabolic markers in cervical cancer using automated digital image
analysis of immunohistochemistry. J Transl Med. 11:1852013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Le QT and Courter D: Clinical biomarkers
for hypoxia targeting. Cancer Metastasis Rev. 27:351–362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
